ELFN1 and neoplasm: Therefore, therapeutics targeting the role of MEIS1 in oxaliplatin resistance are developed and our results suggest that the combination of oxaliplatin with either ELFN1-AS1 ASO or EZH2 inhibitor GSK126 could largely suppress tumor growth and reverse oxaliplatin resistance (Fig. 8e).